Lymphomas

Videos

John M. Burke, MD, of Rocky Mountain Cancer Centers, explains the rationale behind treating an elderly woman with relapsed diffuse large B-cell lymphoma with tafasitamab and lenalidomide after R-CHOP chemotherapy.

A 77-Year-Old Woman with DLBCL

A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.

Targeting CD19 in Diffuse Large B-Cell Lymphoma: Treatment Updates

Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.

A 74-Year-Old Man With Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD, discusses the role of tafasitamab and lenalidomide following the approval of this agent as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Tafasitamab Plus Lenalidomide Approval Generates Excitement for Second-Line DLBCL

Articles

A Biologics License Application was submitted to the FDA for loncastuximab tesirine, an antibody-drug conjugate, as treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

FDA Receives BLA for Lonca in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Targeted Oncology was joined by Kami J. Maddocks, MD, for the discussion of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma in a recent tweet chat.

Tweet Chat Recap: Evaluating Treatment Approaches for Relapsed/Refractory DLBCL

Use of interim positron emission tomography scans to direct patient care has established a new standard treatment approach for patients with limited-stage diffuse large B-cell lymphoma. These findings are from the Intergroup National Clinical Trials Network S1001 study.

PET-Guided Therapy Improves Outcomes in Patients With Limited-Stage DLBCL

A single-center experience demonstrated that certain pre- and post-treatment characteristics may predict outcomes for patients with diffuse large B-cell lymphoma following treatment with a chimeric antigen receptor T-cell therapy.

Clinical Characteristics of DLBCL May Predict Outcomes for Patients Receiving CAR T Cells

Michael Schuster, MD, discusses the efficacy of treatment with selinexor in patients with diffuse large B-cell lymphoma in the SADAL study. 

Phase 2 Trial of Selinexor Shows Durable Responses in DLBCL

In an interview with Targeted Oncology, Salles, explained the unmet needs in DLBCL that may be filled by this new option in the treatment armamentarium and the findings that led to the approval of the combination. 

DLBCL

New content coming soon, please check back later.